These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 27455053)

  • 1. The Effectiveness and Safety of Fluoroquinolone-Containing Regimen as a First-Line Treatment for Drug-Sensitive Pulmonary Tuberculosis: A Systematic Review and Meta-Analysis.
    Lee HW; Lee JK; Kim E; Yim JJ; Lee CH
    PLoS One; 2016; 11(7):e0159827. PubMed ID: 27455053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluoroquinolones for treating tuberculosis (presumed drug-sensitive).
    Ziganshina LE; Titarenko AF; Davies GR
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD004795. PubMed ID: 23744519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moxifloxacin plus standard first-line therapy in the treatment of pulmonary tuberculosis: A meta-analysis.
    Chen Z; Liang JQ; Wang JH; Feng SS; Zhang GY
    Tuberculosis (Edinb); 2015 Jul; 95(4):490-6. PubMed ID: 25964137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sputum culture conversion with moxifloxacin-containing regimens in the treatment of patients with newly diagnosed sputum-positive pulmonary tuberculosis in South India.
    Velayutham BV; Allaudeen IS; Sivaramakrishnan GN; Perumal V; Nair D; Chinnaiyan P; Paramasivam PK; Dhanaraj B; Santhanakrishnan RK; Navaneethapandian GP; Marimuthu MK; Kumar V; Kandasamy C; Dharuman K; Elangovan T; Narasimhan M; Rathinam S; Vadivelu G; Rathinam P; Chockalingam C; Jayabal L; Swaminathan S; Shaheed JM
    Clin Infect Dis; 2014 Nov; 59(10):e142-9. PubMed ID: 25028463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluoroquinolones for treating tuberculosis.
    Ziganshina LE; Squire SB
    Cochrane Database Syst Rev; 2008 Jan; (1):CD004795. PubMed ID: 18254061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moxifloxacin and gatifloxacin for initial therapy of tuberculosis: a meta-analysis of randomized clinical trials.
    Ruan Q; Liu Q; Sun F; Shao L; Jin J; Yu S; Ai J; Zhang B; Zhang W
    Emerg Microbes Infect; 2016 Feb; 5(2):e12. PubMed ID: 26905025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoroquinolones for treating tuberculosis.
    Ziganshina LE; Vizel AA; Squire SB
    Cochrane Database Syst Rev; 2005 Jul; (3):CD004795. PubMed ID: 16034951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moxifloxacin is an effective and safe candidate agent for tuberculosis treatment: a meta-analysis.
    Xu P; Chen H; Xu J; Wu M; Zhu X; Wang F; Chen S; Xu J
    Int J Infect Dis; 2017 Jul; 60():35-41. PubMed ID: 28495364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Fluroquinolones in Newly Diagnosed, Sputum-Positive Tuberculosis Therapy: A Systematic Review and Network Meta-Analysis.
    Li D; Wang T; Shen S; Cheng S; Yu J; Zhang Y; Zhang C; Tang H
    PLoS One; 2015; 10(12):e0145066. PubMed ID: 26669635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoroquinolones for the treatment of pulmonary tuberculosis.
    Moadebi S; Harder CK; Fitzgerald MJ; Elwood KR; Marra F
    Drugs; 2007; 67(14):2077-99. PubMed ID: 17883288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoroquinolones in the management of tuberculous meningitis: Systematic review and meta-analysis.
    Rizvi I; Malhotra HS; Garg RK; Kumar N; Uniyal R; Pandey S
    J Infect; 2018 Oct; 77(4):261-275. PubMed ID: 30017610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Outcomes with Fluoroquinolone-Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis.
    Lee H; Jeong BH; Park HY; Jeon K; Huh HJ; Lee NY; Koh WJ
    Antimicrob Agents Chemother; 2016 Jan; 60(1):471-7. PubMed ID: 26525801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
    Wada M
    Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoroquinolone Sequential Therapy for Helicobacter pylori: A Meta-analysis.
    Kale-Pradhan PB; Mihaescu A; Wilhelm SM
    Pharmacotherapy; 2015 Aug; 35(8):719-30. PubMed ID: 26173786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of non-cavitary pulmonary tuberculosis with shortened fluoroquinolone-based regimens: a meta-analysis.
    Alipanah N; Cattamanchi A; Menzies R; Hopewell PC; Chaisson RE; Nahid P
    Int J Tuberc Lung Dis; 2016 Nov; 20(11):1522-1528. PubMed ID: 27776595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure.
    Devasia RA; Blackman A; Gebretsadik T; Griffin M; Shintani A; May C; Smith T; Hooper N; Maruri F; Warkentin J; Mitchel E; Sterling TR
    Am J Respir Crit Care Med; 2009 Aug; 180(4):365-70. PubMed ID: 19483111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: study protocol for a prospective, multicenter, randomized, open-label, phase II trial.
    Lee JY; Kim DK; Lee JK; Yoon HI; Jeong I; Heo E; Park YS; Lee JH; Park SS; Lee SM; Lee CH; Lee J; Choi SM; Park JS; Joh JS; Cho YJ; Lee YJ; Kim SJ; Hwang YR; Kim H; Ki J; Choi H; Han J; Ahn H; Hahn S; Yim JJ
    Trials; 2017 Feb; 18(1):68. PubMed ID: 28193240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.